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The primary aim of thrombolysis in acute ischemic stroke is recanalization of an occluded intracranial artery. Recanalization is an
importantpredictorofstrokeoutcomeastimelyrestorationofregionalcerebralperfusionhelpssalvagethreatenedischemictissue.
At present, intravenously administered tissue plasminogen activator (IV-TPA) remains the only FDA-approved therapeutic agent
for the treatment of ischemic stroke within 3 hours of symptom onset. Recent studies have demonstrated safety as well as eﬃcacy
of IV-TPA even in an extended therapeutic window. However, the short therapeutic window, low rates of recanalization, and only
modest beneﬁts with IV-TPA have prompted a quest for alternative approaches to restore blood ﬂow in an occluded artery in acute
ischemic stroke. Although intra-arterial delivery of the thrombolytic agent seems eﬀective, various logistic constraints limit its
routine use and as yet no lytic agent have not received full regulatory approval for intra-arterial therapy. Mechanical devices and
approaches can achieve higher rates of recanalization but their safety and eﬃcacy still need to be established in larger clinical trials.
The ﬁeld of acute revascularization is rapidly evolving, and various combinations of pharmacologic agents, mechanical devices,
and novel microbubble/ultrasound technologies are being tested in multiple clinical trials.
1.Introduction
Acute ischemic stroke (AIS) results in focal neurological
deﬁcits referable to a particular cerebral arterial territory.
Most patients presenting with an AIS have arterial thrombi
that occlude extracranial and/or intracranial arteries. Intra-
venously administered tissue plasminogen activator (IV-
TPA) induces thrombolysis and remains the only FDA-
approved thrombolytic agent for AIS within 3 hours from
symptom-onset [1]. Fast dissolution of the thrombi and
arterial recanalization in acute stroke often lead to dramatic
clinical recovery [2].
The last decade has been a period of rapid advances in
the management of AIS patients. Treatment in the acute
phase is largely aimed at restoring blood ﬂow in the aﬀected
artery, partially or completely. Since “time is brain”, timely
recanalization of the occluded cerebral artery might result
in restoration of cerebral perfusion, salvaging threatened
ischemic tissue and improvement clinical outcome [3].
Therefore, success of recanalization therapy depends on
timing as well as the degree of reperfusion. However, as
with myocardial infarction, recanalization and reperfusion
of ischemic tissue may occasionally exacerbate tissue damage
by reperfusion injury, cerebral oedema, and hemorrhagic
transformation [3].
Various pharmaceutical agents and devices, used alone
as well as in combination, have been used to achieve
recanalization in AIS. We aimed to review these approaches
and the current understanding about recanalization in AIS.
2. Pharmacologic Agents
2.1.IntravenousThrombolysiswithTPAwithinThreeHoursof
Symptom Onset. Intravenous (IV) thrombolysis is eﬀective
when used within 3 hours of symptom onset in AIS,
and tissue plasminogen activator (TPA) remains the only
approved agent for this indication [1]. Although IV-TPA2 Stroke Research and Treatment
signiﬁcantly improves patient outcomes, more than 50% of
AIS patients still remain dependent or die. The strict time
window and limited beneﬁts have led to the evaluation of
various alternative therapeutic strategies.
There have been multiple trials with IV-TPA in AIS
on North America and Europe. The National Institute of
Neurological Disorders and Stroke (NINDS) trials (part
1a n d2 )[ 1] included patients treated within 3 hours of
their symptom onset. European Cooperative Acute Stroke
Study (ECASS 1 and 2) [4, 5] recruited patients up to 6
hours. Alteplase ThromboLysis for Acute Noninterventional
TherapyinIschemicStroke(ATLANTIS)trial[6,7]included
NorthAmericanpatients(partA-upto6-hoursandpartBin
a 3–5-hour time window). A pooled analysis of these 6 large
trials revealed that greater beneﬁt is achieved if treatment
is initiated within 90 minutes of symptom onset [Odds
ratio (OR) 2.8, 95% Conﬁdence interval (CI) 1.8–4.5], but
potential beneﬁt exists even beyond 3 hours (OR 1.4, 95%
CI 1.05–1.85 for 180–270 minutes) [8]. This ﬁnding formed
the basis of various studies for evaluating the extended
“therapeutic window” in AIS.
2.2. Intravenous Thrombolysis with TPA beyond Three Hours.
The Diﬀusion-weighted imaging Evaluation for Under-
standing Stroke Evolution (DEFUSE) [9] trial evaluated
74 patients presenting in the 3–6-hour time window with
magnetic resonance imaging (MRI) to identify imaging
patterns that might predict a favourable clinical response
to TPA. The investigators found that a “target-mismatch”
pattern (tissue at risk greater than 120% of tissue already
damaged) on baseline MRI identiﬁed patients who beneﬁted
substantially from early reperfusion, while a “malignant”
pattern (large portion of tissue already damaged) predicted
severe intracranial hemorrhage following reperfusion. A
“benign” pattern deﬁned as small lesion on diﬀusion-
weighted image (DWI), and perfusion-weighted imaging
(PWI) was associated with a favorable clinical response
regardless of subsequent reperfusion.
The Imaging Thrombolysis Evaluation Trial (EPITHET)
[10] evaluated whether IV-TPA given 3–6 hours after stroke
onset promotes reperfusion and attenuates infarct growth
in patients with a mismatch in PWI-DWI MRI. Patients
presenting within 3–6 hour time window underwent a
baseline DWI-PWI MRI and then randomized to IV-TPA or
placebo. MRI was repeated in 3–5 days and at 90 days to
determinewhetherPWI-DWImismatchcanbeusedtoselect
patients who derive beneﬁt from IV-TPA, and whether a
large DWI lesion predicts hemorrhagic transformation. Out
of 101 patients recruited in this trial, 52 received IV-TPA
compared to 49 patients in the placebo group. Mismatch on
PWI-DWI MRI was seen in 85 of 99 (86%) patients. IV-TPA
signiﬁcantly improved reperfusion (and clinical outcomes)
in patients who had mismatch. However; IV-TPA did not
result in lower infarct growth (P = .054) [10].
A recent double-blind randomized placebo-controlled
trial (European Cooperative Acute Stroke Study-ECASS III)
[11] on 821 patients from 19 European countries, evaluated
AIS treated with IV-TPA within 3–4.5 hours. Treated at
a median time of 3 hours 59 minutes, patients receiving
IV-TPA had favourable outcomes compared to placebo
(52.4% versus 45.2%; OR 1.34; 95% CI 1.02–1.76; P =
.04). Although the incidence of symptomatic intracranial
hemorrhage(SICH)washigherwithTPA(2.4%versus0.2%;
P = .008), mortality did not diﬀer signiﬁcantly between
the two groups (7.7% and 8.4%, resp.; P = .68) [11]. The
ongoingInternationalStrokeTrialIII(IST-III)[12],aimedat
evaluating 3100 patients, is evaluating the safety and eﬃcacy
of IV-TPA within 6 hours of stroke onset.
Although arterial recanalization is one of the primary
aims of thrombolysis, this phenomenon was not evaluated
in major IV-thrombolysis trials [1, 4, 5, 7, 11]. Overall
recanalization rates have varied from 30% to 92% during
ﬁrst 6–24 hours [13]. Higher recanalization ratea were
noted during ﬁrst hour (45%), followed by 11% during
the second hour and only 7% additional patients achieved
recanalization during next 4 hours [14]. Recanalization rates
are determined by the site of occlusion also, with lower rates
observed in proximal than in distal occlusions, probably due
to higher clot burden. While almost one-third of middle
cerebral artery (MCA) occlusions recanalize with IV-TPA,
this occurs only in about 10% of patients with distal internal
carotid artery (ICA) occlusions [15]. Furthermore, some
associated conditions like coexisting carotid artery disease
and diabetes mellitus may reduce the rates of recanalization
[13]. Rha and Saver, in a recent meta-analysis found that
theoverallrecanalizationratewithanyinterventionwas55%
[3].
3. Thrombolysis with Other FibrinolyticAgents
3.1. Desmoteplase. Desmoteplase is a ﬁbrin-speciﬁc and
nonneurotoxic protein derived from the saliva of vampire
bat. The Desmoteplase in Acute Ischemic Stroke (DIAS-1)
trial was a dose-ﬁnding randomized, double-blind, placebo
controlled, multicenter, phase II trial designed to evaluate
the safety and eﬃcacy of IV-Desmoteplase given in the 3–
9 hour window [16]. In addition to the recanalization, DIAS
trialevaluatedreperfusionasanimportantoutcomemeasure
using the PWI-DWI mismatch. In initial phase of the trial,
patients were randomized to ﬁxed doses of Desmoteplase
(25mg, 37.5mg, or 50mg) or placebo. However, this was
stopped early due to higher rates of SICH. In part II,
weight-adjusted doses (62.5µg/kg, 90µg/kg, and 125µg/kg)
were investigated. Reperfusion was assessed 4 to 8 hours
posttreatment and deﬁned as either ≥30% reduction of
mean transit time volume or ≥2 point improvement in
recanalization. Early reperfusion correlated favourably with
clinical outcome (52.5% versus 24.6%; P<. 002) and SICH
occurred in 2.2%.
Eﬃcacy and safety of IV desmoteplase was further
evaluated in the Dose Escalation of Desmoteplase in Acute
Stroke (DEDAS) study [17], in patients treated within 3 to
9 hour time window. Eligibility criteria included baseline
NIHSS scores of 4–20 and MRI evidence of PWI-DWI
mismatch. Results of DEDAS were almost similar to the
DIAS trial. At a dose of 125µg/kg, Desmoteplase appeared to
improve clinical outcome, especially in patients fulﬁlling the
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study, was initiated with an additional attempt to investigate
the clinical eﬃcacy and safety of Desmoteplase in patients
with “tissue-at-risk”, as assessed by PWI-DWI MRI or
perfusion CT [18]. In this randomized, placebo-controlled,
double-blind, dose-ranging study, patients “tissue-at-risk”
were randomly assigned to 90microgm/kg Desmoteplase,
125 microgm/kg Desmoteplase, or placebo within 3–9
hours after symptom onset. The primary endpoint was
clinical response rate at day 90. Secondary endpoints
included change in lesion volume between baseline and
day 30, rates of SICH and mortality. Median baseline
NIHSS score was 9 points and only 30% of the patients
had a visible arterial occlusion at presentation. DIAS-2
study failed to show the beneﬁt of Desmoteplase given 3–
9 hours after the stroke onset using the MRI mismatch
model.
4. Ancrod
Ancrod (Viprinex) is an enzyme derived from pit viper
venom with deﬁbrinating properties. The Stroke Treatment
with Ancrod Trial (STAT) [19], a randomized, parallel-
group, double-blind, placebo-controlled trial recruited
patients from 48 centers in the United States and Canada.
A total of 500 patients were randomly assigned to receive
Ancrod (n = 248) or placebo (n = 252) as continuous
72-hour IV-infusion beginning within 3 hours of stroke
onset, followed by infusions lasting 96 and 120 hours. The
Ancrod regimen was designed to decrease plasma ﬁbrinogen
levels from 1.18 to 2.03micromol/L. Favorable outcome was
achieved by more patients in the Ancrod group (42.2%
versus 34.4% with placebo; P = .04) with a trend toward
more SICH in the Ancrod group (5.2% versus 2.0%; P =
.06). However, phase-III trials with Ancrod (ASP I and II:
Ancrod Stroke Program) used within 6 hours of symptom
onset had to be terminated prematurely due to safety
concerns [12]. Levy et al. suggested that some modiﬁcations
to Ancrod dosing may substantially improve eﬃcacy while
reducing SICH [20].
5. Other Agents
Although not thrombolytic, heparin and glycoprotein
IIb/IIIa receptor antagonists have been investigated in AIS.
In a study of 312 patients treated with low molecular weight
heparin (Nadroparin) within 48 hours of symptom onset,
the investigators evaluated 2 doses of Nadroparin against
placebo and observed a signiﬁcant dose-dependent eﬀect in
favor of Nadroparin (P = .005). However, no signiﬁcant
diﬀerences were observed in secondary outcomes at 10 days
[21]. The Heparin in Acute Embolic Stroke Trial (HAEST)
compared Dalteparin against aspirin in atrial ﬁbrillation
[22]. Patients were recruited within 30 hours of symptom
onset. The frequency of recurrent AIS during the ﬁrst 14
days was 19/244 (8.5%) in Dalteparin-allocated patients
versus 17/225 (7.5%) with aspirin (OR1.13, 95% CI 0.57–
2.24). The secondary events (SICH, stroke progression and
death) during the ﬁrst 14 days also revealed no additional
beneﬁt of Dalteparin. There were no signiﬁcant diﬀerences
in functional outcome or death [22].
Abciximab, a chimeric mouse/human monoclonal anti-
body with high aﬃnity for platelet glycoprotein IIb/IIIa
receptor, has been used as an adjunct to endovascular
procedures or a thrombolysis in animal model [23]a n df o r
treatment of patients with AIS [24]. Furthermore, a dose-
escalation study in 74 subjects suggested low risks of SICH
when it was given up to 24 hours after stroke onset [25].
Similar safety and eﬃcacy were noted in a larger randomized
trial on 400 AIS subjects treated within 6 hours [26]. Despite
this , the Abciximab in Emergency Treatment of Stroke Trial
Abciximab (AbESTT-II), a phase III trial was terminated
prematurely due to an unfavourable beneﬁt-risk proﬁle [27].
Within 5 days of enrolment, 5.5% of Abciximab-treated
(compared to 0.5% on placebo) patients developed SICH
(P = .002). The trial did not demonstrate any improvement
in outcomes with Abciximab.
The Reopro Retevase Reperfusion of Stroke Safety Study
(ROSIE)isanongoingopen-label,doseescalation,safetyand
proof-of-principle study [12]. It is including AIS patients
within 3–24 hours of symptom onset, with a disabling
neurological deﬁcit, NIHSS score ≤ 16 points, and evidence
of a perfusion deﬁcit on PWI MRI and MRA. This trial is
looking into the safety and eﬃcacy of Abciximab (ReoPro)
and Reteplase (Retevase) in reperfusing the ischemic tissue.
ROSIE-CT is similar to ROSIE and includes patients ineligi-
bleforMRI,andCTperfusionwouldassessreperfusion[12].
Both these trials have completed recruitment and the results
are awaited.
5.1. Intra-Arterial Thrombolytics. Intra-arterial (IA) throm-
bolysis oﬀers potential advantage of higher concentrations
of thrombolytic delivered to the clot with reduced systemic
exposure and the possibility of higher rates of recanalization.
While there are currently no FDA-approved IA thrombolytic
agents, several uncontrolled and anecdotal studies have
evaluated IA thrombolysis in AIS.
In an open clinical series, IA thrombolysis has shown
higher early recanalization rates (50% to 80%) than IV
therapy (30% to 50%) [15] .T h eP r o l y s ei nA c u t eC e r e b r a l
Thromboembolism (PROACT-I) trial was a randomized,
double-blinded,placebo-controlledphaseIIstudyevaluating
the recanalization safety and eﬃcacy of IA recombinant
prourokinase(r-proUK)inpatientswithsymptomaticM1or
M2 MCA occlusions at 2 hours after initiation of treatment
[28]. Of 1314 patients screened, 40 (3%) were randomized
to r-proUK (6mg) or placebo infused IA over 2 hours.
At the end of infusion, signiﬁcantly higher recanalization
rates were observed in the treatment group (57% versus
14.3%; P = .017). To determine the phase III clinical safety
and eﬃcacy of r-proUK, PROACT II was conducted [29].
Patients presenting within 6 hours of AIS were randomized
to either 9mg of IA r-proUK plus heparin or heparin alone,
over 2 hours. Of 12323 patients screened, 180 patients were
randomized. With 5.3 hours as the median time to initiate
therapy, 66% of the patients in the treatment arm achieved
MCA recanalization compared with 18% in “heparin only”
arm (P<. 001). Likewise, 40% of the patients in the4 Stroke Research and Treatment
treatment group achieved functional-independence at 90
days compared with 25% in “heparin only” arm (OR 2.13,
95% CI 1.02–4.42; P = .04). Despite higher rates of
ICH in treatment group (10% versus 2%; P = .06), no
diﬀerences were noted in mortality between the two groups
[29]. Based on a reanalysis of the PROACT II trial, patient
selection with a noncontrast CT scoring could identify
patients who beneﬁt from IA thrombolysis once the 3-
hour time window for intravenous thrombolysis has passed
[30].
6.Combined Intravenous-Intra-Arterial
Thrombolysis
IV thrombolysis is the fastest way to initiate treatment.
Conversely, IA thrombolysis requires an experienced inter-
ventionalist, angiographic facilities, and time to deploy the
endovascular in the culprit vessel. This imposes treatment
initiation delays. To achieve better rates of recanalization and
clinical outcomes, a combination of these two modalities
in AIS have been evaluated. The ﬁrst pilot study was the
Emergency Management of Stroke (EMS) trial, a random-
ized, placebo-controlled multicenter study designed to test
the feasibility, relative beneﬁts, and risks of combined IV/IA
thrombolysis [31]. Within 3 hours of stroke onset, the IV/IA
treatment group (n = 17) received 0.6mg/kg of IV-TPA
(10% bolus, 60mg maximum over 30 minutes) followed
within 2 hours by local IA-TPA (maximum 20mg). The
control group (n = 18) received IV placebo followed
similarly by IA-TPA. Although the treatment group showed
higher rates of angiographic recanalization than controls
(54% versus 10%; P = .03) and lower NIHSS scores at
90 days, signiﬁcantly higher mortality was noted in the
treatment group (29% versus 5.5%; P = .06).
To further investigate the combined approach, the
Interventional Management of Stroke (IMS-I) study was
performed [32]. This multicenter open-label trial had the
design similar to EMS and aimed at testing the feasibility and
safety of combined IV/IA-TPA within 3 hours of symptom
onset by comparing outcomes to matched (age and baseline
NIHSS) historical controls from the NINDS trial [1]. The
combination therapy was found to be feasible with safety
similar to IV-TPA alone. Outcomes in the IMS subjects were
alsosigniﬁcantlybetterat3monthsthantheplacebosubjects
of NINDS trial [32]. Encouragement from these ﬁndings led
to the ongoing IMS-III, which is a randomized, multicenter,
open-label clinical trial of 900 subjects assessing whether the
combined IV/IA approach is superior to standard IV-therapy
alone when initiated within 3 hours of symptom onset [12].
Pending further short-and long-term data on the beneﬁt
of combined IV/IA therapy compared with IV therapy
alone, current guidelines suggest that IV-therapy should
not be withheld from eligible patients. IA-thrombolysis is
a therapeutic option for selected patients who have major
stroke of <6 hours duration due to occlusions of the MCA
and not suitable for IV-TPA. Treatment requires the patient
to be at an experienced stroke center with immediate access
to cerebral angiography and qualiﬁed interventionalists [32].
7. Devices for Treatment of
Acute Ischemic Stroke
Pharmacologic agents have risks and contraindications that
have prompted the development of devices as alternative
ways to restore blood ﬂow. In addition, the eﬃcacy of
pharmacologic agents can be augmented by a variety of
devices. The Merci Retrieval System (Concentric Medical,
Inc.) is an FDA-approved device comprised of a tapered
nitinol wire with helical loops of decreasing diameter at its
distal end. It is advanced through a microcatheter directly
through the clot and then released to acquire the helical loop
shape and retrieve the clot.
To evaluate safety and eﬃcacy of Merci device,
the Mechanical Embolus Removal in Cerebral Ischemia
(MERCI) single arm, multicenter trial evaluated 141 patients
presenting within 3–8 hours of symptom-onset [33]. With
a mean procedural time of 2.1 hours, 48% of patients had
successful recanalization of MCA, terminal ICA, vertebral
or basilar artery. This was in comparison to 18% recanal-
ization in the PROACT-II historical control arm (P<
.0001) [29]. Adjuvant therapy (IA-TPA with or without
angioplasty/snare) was needed in 51 of the 141 eligible
patients. Clinically signiﬁcant procedural complications and
I C Hw e r es e e ni n7 . 1 %a n d7 . 8 % ,r e s p e c t i v e l y .M o r ep a t i e n t s
with successful recanalization achieved good neurological
outcomes at 90 days than those with unsuccessful recanal-
ization (46% versus 10%; P<. 0001) [34].
FDA approval of the MERCI Retriever as a device for
clot removal in AIS engendered criticism from the stroke
neurologists who cited double standards between drug and
deviceregulatoryrequirementsforapproval[35].Despitethe
FDA approval, the clinical utility of the MERCI device has
not been established.
The ongoing Magnetic Resonance and Recanalization
of Stroke Clots Using Embolectomy (MR-Rescue) trial uses
MRI to compare embolectomy with the Merci devices to
standard treatment in AIS patients presenting within 8
hours of symptom onset [12]. Mechanical devices oﬀer
somedistinctadvantagesoverpharmacologicalthrombolysis
like faster recanalization [15], eﬀectiveness in removing
large thrombi, and lower risk of SICH. However, these
devices require bulky catheters and may cause endothelial
damage, vessel wall perforation, and intracranial bleeding.
Recanalization is believed to be the key for better outcomes
in AIS. However, it has not been evaluated routinely in
the clinical trials. Comparative rates of recanalization and
methodology of some of the major trials in acute stroke are
summarized in the Table 1.
8.CombiningPharmacology andDevices
Simple mechanical clot disruption with microcatheter
or microwire, or aggressive mechanical clot disruption
(AMCD) with a snare or balloon angioplasty, in conjunction
with thrombolysis, may achieve higher rates of recanal-
ization. Quershi et al. treated 19 patients with balloon
angioplasty and/or snare in addition to IV/IA thrombolysis,
f o rb o t hp r o x i m a la n dd i s t a lo c c l u s i o n s[ 36]. AlthoughStroke Research and Treatment 5
Table 1: Arterial occlusions and recanalization patterns in some clinical trials in acute ischemic stroke.
TRIAL Treatment Number of
patients
Highest reported
recanalization rate (%)
Assessment of
recanalization
NINDS
Active IV-TPA 312 — None
Control Placebo 312 —
DIAS
Active
Desmopletase (IV)
71 (Total) 49
MRA-complete or
partial recanalization Part-l 25 mg 16 56
37.5/50mg 13 46
Part-2 62.5mg/kg 13 23
90mg/kg 15 47
125mg/kg 14 71
Control Placebo 26 (Total) 19
Part-1 16 19
Part-2 10 20
PROACT-II
(TIMI 2 + 3)
Active lAr-proUK 121 66 Cerebral angiography
(TIMI 2 + 3) Control Placebo 59 18
EMS
Active IV + IA TPA 11 81 Cerebral angiography
Control Placebo + IA TPA 10 50
MERCI
Active MERCI ± Lytic
Cerebral angiography
(any recanalization)
MCA 80 45
ICA 47 53
VAIBA — 14 50
Control ——
CLOTBUST
(at 2 hours)
Active IV-TPA + TCD 63 38 TCD
Control IV-TPA 63 13
TRUMBI
Active IV-TPA + Ultrasound 14 29.3 MRA
Control IV-TPA 12 50.0
recanalization rate was 86%, the mortality rate was 53%.
Noser et al. employed AMCD by microcatheter/microwire
clot maceration, angioplasty, stent, or snare in 32 patients
(adjuvant to IA and/or IV thrombolysis) [37]. Seventy-ﬁve
percent of patients showed recanalization with favorable
outcome in 59%. The mortality rate was 12.5%.
Endovascular therapy (percutaneous transluminal
angioplastywithorwithoutstentplacement)incombination
withIV/IAthrombolysis+/−glycoproteinIIb/IIIainhibition
hasbeenusedforMCAasw ellase xtracranialICAoc clusions
with varying results in several small case series[38–40].
Multi-MERCI was an international, multicenter,
prospective, single-arm trial of thrombectomy in patients
with large vessel stroke treated within 8 hours of symptom-
onset [41]. It allowed inclusion of patients with persistent
large vessel occlusion after IV-TPA and permitted use
of adjuvant IA thrombolysis, if the device failed. One
hundred sixty-four patients with a median NIHSS of 19
points underwent mechanical thrombectomy. Successful
recanalization was achieved in 57.3% of treatable vessels
and improved to 69.5% when mechanical embolectomy was
combined with IA-TPA. The trial concluded that favourable
clinical outcomes (36% of patients) were signiﬁcantly related
to arterial recanalization. Clinically signiﬁcant procedural
complications were observed in 5.5% of patients [41].
Ultrasound exposure has been shown to help in dissolv-
ing the thrombus [42]. Experimental evidence suggests that
thrombolytic eﬀect of IV-TPA is substantially enhanced by
ultrasound, particularly if used in low MHz-kHz frequency
range. Ultrasound exposure causes reversible disaggregation
of uncrosslinked ﬁbrin ﬁbers and microcavity formation
in the shallow layers of thrombus, allowing increased
penetration of TPA into the clot and enhancing ﬂow with
microstreaming and vessel dilation [43–45].
Lytic activity of IV-TPA can be safely augmented with
TCD. The Transcranial low-frequency Ultrasound Mediated
Thrombolysis in Brain Ischemia (TRUMBI) trial, in a phase
II randomized, multicenter study tested the eﬃcacy of low-
frequency ultrasound exposure along with IV-TPA in AIS
[46]. An experimental, nonimaging therapeutic device oper-
ating with approximately 300kHz pulsed wave ultrasound
was used. The study was terminated after enrolling only
14 patients in the treatment arm due to a signiﬁcantly
high incidence of SICH. These harmful bioeﬀects of low-
frequency ultrasound were probably due to lack of prior
human dose-escalation studies. Using ultrasound in the
mega-Hertz range with transcranial duplex equipments was
recently tested by Eggers et al. [47]. Patients with acute
occlusions of MCA were randomized into a target group
receiving 1-hour transcranial continuous insonation using6 Stroke Research and Treatment
a 1.8-MHz Doppler ultrasound probe or a control group
during standard thrombolysis with IV-TPA. Patients in the
ultrasoundgroupshowedgreaterneurologicalimprovement.
However, 15.8% of patients developed SICH as compared to
5.6% in the controls (P = .60).
Combined Lysis of Thrombus in Brain Ischemia Using
Transcranial Ultrasound and Systemic tPA (CLOTBUST)
wasaphaseIIrandomized,double-blind,placebo-controlled
trial evaluating the feasibility and safety of IV-TPA and con-
tinuous2-hourmonitoringwithcommerciallyavailableFDA
approved 2MHz diagnostic TCD devices [48]. Complete
recanalization or dramatic clinical recovery within 2 hours
after administration of IV-TPA occurred in 49% of those
receiving TCD compared with 30% receiving placebo (P =
.03). Recently, we reported the feasibility, safety, and eﬃcacy
of ultrasound-assisted thrombolysis in Singaporean patients
[49].
In the pivotal CLOTBUST trial, primary endpoint was
achieved in 49% of patients in the target-group and 30%
in the controls (P = .03) [48]. CLOTBUST was not
powered to evaluate the eﬃcacy of ultrasound-enhanced
thrombolysis in improving functional outcome. A trend
toward better functional outcomes in patients treated with
continuous TCD monitoring merits a pivotal phase III
clinical trial. However, larger number of patient needed to
power such a clinical trial coupled with small number of
neurosonologists and emergence of newer therapies posed
serious limitations. Our multicenter collaborative group
prospectively implemented a protocol for TCD assessment
of intracranial recanalization with IV-TPA [50]. We aim
to determine whether early recanalization is independently
associated with better 3-month outcome in AIS patients with
intracranial arterial occlusions. Additionally, it would seek
to recruit and train centres and operators before embarking
into a large randomized phase III clinical trial.
The IMS-II trial evaluated IV versus IV/IA TPA along
with the EKOS MicroLysus catheter (Bothell, WA), which
directly exposes the clot to low power ultrasound [51]. The
recanalization rate of grade 2 and 3 in EKOS-treated subjects
in IMS II was 45.5% as compared with 30% in IMS I-treated
subjects (P = .26) [51].
One novel method of enhancing the rates of recanaliza-
tionbyIV-TPAcouldbetheuseofgaseousmicrospheres(µS)
during TCD monitoring. Gaseous µSa r eu s e da sc o n t r a s t
agents for ultrasound imaging and their exposure to pulsed
TCD leads to their compression, oscillation, and collapse.
These physical alterations could transmit mechanical energy
momentum to surrounding ﬂuids, accelerate the residual
ﬂow, and possibly help in disrupting the thrombus [52, 53].
Recently, promising human studies were done with TCD-
activated ﬁrst generation gaseous µS as an adjunctive therapy
with IV-TPA [54, 55]. The Safety Study of Microbubbles
With Transcranial Ultrasound and TPA in the Management
of Acute Ischemic Stroke (TUCSON) trial,was initiated with
3rd generation submicron-sized microspheres [56]. This was
a phase I/II, randomized, placebo-controlled, single-blind,
dose escalation, safety/eﬃcacy study, however, the study had
to be terminated prematurely due to an increased SICH in
the 2nd cohort [12].
Various other innovative approaches have been adopted
to achieve better clinical outcomes in AIS. The NeuroThera
Eﬀectiveness and Safety Trial–2 (NEST-2) tested the safety
and eﬃcacy of transcranial laser therapy (TLT) [57]. This
double-blind, randomized study compared TLT treatment
to sham control included 660 patients (331 received TLT
and 327 received sham) within 24 hours of symptom onset.
More patients in the TLT group achieved favorable outcome
versus the sham group (P = .094) but no prespeciﬁed test
achieved signiﬁcance. A post-hoc analysis of patients with a
baselineNIHSSscoreof <16showedafavourableoutcomeat
90 days on the primary endpoint (P<. 044). Mortality rates
and serious adverse events did not diﬀer between groups. A
deﬁnitive trial with reﬁned baseline NIHSS criteria is being
planned.
9. Conclusions
Acute is a chemic stroke which continues to be a devastating
disease. Early access to deﬁnitive therapy remains the key
for a better outcome. The search for newer, more eﬀective
and yet, safer pharmacological, interventional, and com-
bined treatments continues. The diversity of new emerging
approaches makes stroke an exciting and rapidly evolving
ﬁeld.
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